Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost Eluting Contact Lens for Glaucoma
NCT04500574Phase 1Terminated
- Sponsor
- Massachusetts Eye and Ear
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of latanoprost in Glaucoma and ocular hypertension (3 arms), sponsored by Massachusetts Eye and Ear. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Change in Intraocular Pressure at 6 weeks. Started Apr 2024; status: terminated.
02
Drugs
latanoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT04500574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500574.